Certara acquires Pinnacle 21 for $310M in cash and stock

Certara, Inc.

Enterprise value $310M: $250M cash + $60M in newly issued Certara shares.
Acquisition expected to be immediately accretive to revenue, revenue growth, and adjusted EBITDA margin.
Pinnacle 21 provides FDA/PMDA-required clinical data standardization software; 22 of top 25 pharma companies are customers.
Transaction unanimously approved; expected to close early Q4 2021 subject to regulatory approvals.
Deal expands Certara's biosimulation platform into data fitness and regulatory software.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.